Stock Analiz

Purple Biotech Ltd. PPBT

Biotechnology: Pharmaceutical Preparations · IPO 2015 · data as of November 13, 2026

$1.63Market cap $3M
Open the interactive analysis →

Purple Biotech Ltd. (PPBT) is a healthcare company listed in the US with a market value of about $3M.

Its overall Stock Analiz score is 0.8 out of 5 (weak). The strongest part is financial health (4/5); the weakest is value (0/5).

Key numbers: a 5-year average ROIC of -37%.

About Purple Biotech

Purple Biotech is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2015. It was profitable in 6 of the last 10 years in our data.

Score: 0.8 / 5

Value0/5
Future growth0/5
Track record0/5
Financial health4/5
Shareholder returns0/5

Checks passed

  • More cash than debt, or low debt to equity
  • Interest covered more than 5 times
  • Debt below 3 years of free cash flow
  • Liabilities below 60% of assets

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • Profit margin improving

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S—
P/B0.3
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield-213.4%
Shareholder yield0.0%
Intrinsic value vs. price—

Growth and quality

Revenue growth (1 yr)—
Revenue growth (5 yrs, per year)—
EPS growth (5 yrs, per year)-59.4%
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)—
ROIC (5-yr avg.)-37.1%
Profitable years (of last 10)6
Years paying a dividend—

Financials, last 10 years

Fiscal year2025202420232022202120202019201820172016
Revenue——————————
Net income-$26M-$7M-$20M-$22M$18M$29M$5M$5M$12M$12M
Free cash flow-$6M—-$20M-$17M-$489000$2M-$2M-$8M-$9M-$6M
EPS (diluted)$-16.22$-4.45$-12.22$-13.32$10.96$17.64$3.32$3.20$7.48$7.45
Net margin——————————
ROIC——-51.4%-38.1%-21.9%-12.6%-54.2%-58.8%-127.6%-42.4%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

Frequently asked questions

Does Purple Biotech pay a dividend?

Not currently.

Is Purple Biotech a good stock to buy?

We do not give buy or sell advice. Purple Biotech scores 0.8 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.